

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Multiple Technology Appraisal

Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes

Final updated stakeholder list of consultees and commentators

Consultees

Companies/distributors

- Advanced Therapeutics UK Ltd
- Air Liquide Healthcare Ltd
- CamDiab Ltd
- DexCom International Ltd
- Medtronic Ltd
- Tandem Diabetes Care, Inc
- Ypsomed UK

Patient/carer groups

- Diabetes UK
- Juvenile Diabetes Research Foundation (JDRF)
- National Children and Young People's Diabetes Network

Professional groups

- Diabetes Technology Network - UK
- The Royal College of Physicians
- The Royal College of Pathologists

Others

- Department of Health and Social Care
- NHS England
- Welsh Government

Commentators (no right to submit or appeal)

General

- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare Products Regulatory Agency
- Scottish Medicines Consortium
- Welsh Health Specialised Services Committee

Comparator companies

- Abbott Diabetes Care
- Beta Bionics (**confidentiality agreement not signed, not participating**)
- Bigfoot Biomedical (**confidentiality agreement not signed, not participating**)
- Diabeloop (**confidentiality agreement not signed, not participating**)
- Insulet International Ltd
- Kaleido (**confidentiality agreement not signed, not participating**)
- Lilly (**confidentiality agreement not signed, not participating**)
- Mylife Diabetescare (**confidentiality agreement not signed, not participating**)
- Roche (**confidentiality agreement not signed, not participating**)
- Terumo (**confidentiality agreement not signed, not participating**)
- Tidepool (**confidentiality agreement not signed, not participating**)

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the list, and which organisations we should include that have a particular focus on relevant equality issues.

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate; other groups (for example, the British National Formulary).

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.